Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Trial watch: Radioimmunotherapy for oncological indications
Norma Bloy
, Jonathan Pol
, Gwenola Manic
, Ilio Vitale
,
Alexander Eggermont
, Jérôme Galon
, Eric Tartour
, Laurence Zitvogel
, Guido Kroemer
, Lorenzo Galluzzi
Research output
:
Contribution to journal
›
Review article
›
peer-review
51
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Trial watch: Radioimmunotherapy for oncological indications'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Oncologic
100%
Radiation Therapy
100%
Antineoplastic Agents
100%
Radioimmunotherapy
100%
Immunotherapeutics
50%
Cancer Cells
50%
Clinical Trials
50%
Recent Advances
50%
Radiotherapy
50%
Chemotherapy
50%
In Cancer
50%
Treatment Modalities
50%
Apoptosis
50%
Cancer Patients
50%
Transformed Cells
50%
Immunostimulatory
50%
Radiation Effects
50%
Tumor-specific Immune Response
50%
Immunogenic Cell Death
50%
Anticancer Immune Response
50%
Abscopal Effect
50%
Proliferative Arrest
50%
Cell-extrinsic
50%
Out-of-field
50%
Damage-associated Molecular Patterns
50%
Extrinsic Mechanism
50%
Medicine and Dentistry
Radiation Therapy
100%
Radioimmunotherapy
100%
Immune Response
66%
Anticarcinogen
66%
Malignant Neoplasm
33%
Cancer Cell
33%
Clinical Trial
33%
Specific Tumor
33%
Programmed Cell Death
33%
Immunomodulating Agent
33%
Immunogenic Cell Death
33%
Transformed Cell
33%
Abscopal Effect
33%
Chemotherapy
33%
Immunology and Microbiology
Immune Response
100%
Cell Death
50%
Immunomodulating Drugs
50%
Cancer Cell
50%
Transformed Cell
50%
Neuroscience
Radiation Therapy
100%
Anticarcinogen
66%
Immunomodulating Drugs
33%
Cell Death
33%